Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Bone marrow transplantation·2026

Same author

Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Bone marrow transplantation·2026

Same author

Enhanced peripartum hemostatic management does not decrease postpartum hemorrhage incidence in hemophilia carriers: the Pregnancy and Inherited Bleeding Disorders study.

Journal of thrombosis and haemostasis : JTH·2026

Same author

How to set up a pregnancy heart team.

International journal of cardiology. Congenital heart disease·2025

Same author

Cerebral toxoplasmosis in the twenty-first century.

AIDS (London, England)·2025

Same author

Blood pressure patterns during pregnancy and early postpartum in preeclampsia with severe features: predictors of chronic hypertension.

Pregnancy hypertension·2025

Search research articles

Related Experiment Video

Updated: May 8, 2026

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Published on: January 26, 2024

[Thrombocytopenia during pregnancy].

C Rokx¹, R M Swart, A A van Houten

¹Erasmus Medisch Centrum, Rotterdam.

Nederlands Tijdschrift Voor Geneeskunde

|August 16, 2013

Summary

This summary is machine-generated.

Severe thrombocytopenia in pregnancy requires prompt diagnosis and multidisciplinary care. This case highlights immune thrombocytopenia (ITP) management challenges, even with standard treatments, emphasizing the need for tailored approaches in pregnant patients.

More Related Videos

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

Related Experiment Videos

Last Updated: May 8, 2026

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Published on: January 26, 2024

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

Area of Science:

Obstetrics and Gynecology
Hematology
Perinatology

Background:

Thrombocytopenia in pregnancy presents diagnostic challenges.
Early identification is critical for effective management and maternal-fetal outcomes.
Severe cases necessitate a collaborative approach involving multiple medical specialties.

Purpose of the Study:

To present a case of severe immune thrombocytopenia (ITP) in a pregnant patient.
To discuss the differential diagnosis of thrombocytopenia during gestation.
To highlight management strategies for ITP in pregnancy.

Main Methods:

Case report of a 30-year-old woman at 35 weeks gestation.
Review of differential diagnoses for thrombocytopenia in pregnancy.
Discussion of ITP management in the context of pregnancy.

Main Results:

The patient presented with preterm rupture of membranes and severe thrombocytopenia.
Immune thrombocytopenia (ITP) was diagnosed as the cause.
Standard first-line treatments (corticosteroids, IVIg) were ineffective in resolving the severe thrombocytopenia.

Conclusions:

Immune thrombocytopenia (ITP) poses significant management challenges during pregnancy.
Refractory cases may require alternative therapeutic strategies.
A multidisciplinary team is essential for optimal care of pregnant patients with severe thrombocytopenia.